Type I interferon drives immune-cell plasticity and lung injury after irradiation in mice

Blocking type I interferon signaling reduced inflammation and fibrosis after focal lung irradiation in mice by limiting ILC2-to-ILC1 plasticity.

KEY POINTS

  • This preclinical study from City of Hope investigated how innate lymphoid cells (ILCs) contribute to radiation-induced lung injury (RILI) and subsequent fibrosis. Researchers developed a restricted-field irradiation model in wild-type and immunodeficient mice, delivering 60 Gy in one fraction to a 7-mm-diameter region of the left lung using a 300-kV X-ray system. Histology demonstrated inflammatory infiltration and alveolar wall thickening at two weeks, followed by fibrotic changes at two months, reproducing selected pathological features of radiation pneumonitis and fibrosis.
  • Innate lymphoid cells were important contributors to the radiation-induced inflammatory response. Lung inflammation developed in both wild-type and Rag2-deficient mice lacking functional T and B cells, but was significantly attenuated in Rag2/Il2rg double-knockout mice, which additionally lack NK cells and ILCs. Inflammatory scoring was lower in the double-knockout mice than in the T/B-cell-deficient group (p=0.0010). ILC accumulation peaked approximately 10 days after irradiation, coinciding with increased lung IFN-γ and TNF production.
  • Radiation shifted the pulmonary ILC population from an ILC2-dominant toward an ILC1-like phenotype. At day 10, the proportion of ST2−c-kit− ILC1 cells increased significantly (p<0.0001), while ST2+ ILC2 cells decreased (p<0.0001), despite no significant change in total ILC frequency. In adoptive-transfer experiments involving seven mice per treatment condition, transferred ILC2s acquired ILC1-like surface markers following irradiation, supporting radiation-associated cellular plasticity rather than expansion of only pre-existing ILC1 populations.
  • Radiation also altered ILC cytokine production toward a proinflammatory profile. At day 10, the frequency of IFN-γ-producing ILCs increased (p=0.0021) and TNF-producing ILCs increased (p=0.0082), while IL-13-producing ILCs decreased (p<0.0001). Amphiregulin, IL-17A, and IL-22 expression did not change significantly, indicating selective functional reprogramming rather than uniform activation of every ILC-associated pathway. The radiation-induced cytokine shift was substantially diminished in mice lacking ILCs.
  • Single-cell RNA sequencing identified 1,702 ILCs among 25,932 quality-controlled cells, resolving three ILC1-like clusters, one ILC2 cluster, and one ILC3 cluster. Pseudotime analysis suggested a transition from ILC2-associated genes such as Gata3 and Areg toward ILC1-associated Tbx21 and Ifng, accompanied by enrichment of type I interferon-response pathways. Lung IFN-β protein increased after irradiation (p=0.0027), supporting a potential upstream mechanism. However, the sequencing analysis pooled cells from three mice per group, limiting independent biological replication of these transcriptional observations.
  • IFN-β stimulation was sufficient to induce ILC2-to-ILC1-like reprogramming in vitro. Purified mouse ILC2s exposed to 1 ng/mL IFN-β for 48 hours showed increased ILC1-like phenotype (p=0.0019), increased expression of the ILC1 transcription factor T-bet (p=0.0101), reduced GATA3 expression, and increased IFN-γ production (p=0.0014). Human peripheral blood mononuclear cells similarly showed a shift toward an ILC1-like profile after IFN-β stimulation, but the human experiment used six technical replicates from one commercial cell preparation, not independent validation in irradiated human lungs.
  • Blocking type I interferon signaling reduced both acute inflammation and subsequent fibrosis. Mice received 500 μg anti-IFNAR1 antibody intraperitoneally on days 0, 2, 4, 6, and 8 after irradiation, suppressing the ILC1-like shift and partially restoring ILC2 populations. Lung inflammatory scores decreased at two weeks (p=0.0462), while histological fibrosis scores and collagen deposition were significantly reduced at two months. However, the model used an unusually high single 60-Gy dose, lacked clinical CT-based dose reconstruction, and did not include tumor-bearing animals or assess whether IFNAR1 blockade compromises radiation-induced antitumor immunity.

CLINICAL TAKEAWAY

This study identifies type I interferon-mediated ILC2-to-ILC1 plasticity as a potential mechanism contributing to radiation pneumonitis and lung fibrosis, with IFNAR1 blockade providing experimental normal-tissue protection. Although the findings suggest a new therapeutic target for reducing thoracic radiation toxicity, they remain preclinical, and both human pulmonary validation and preservation of antitumor immunity must be demonstrated before interferon-pathway inhibition can be considered clinically.

SOURCE

Nature Communications

Browse more research Suggest a correction